RYTM - Good point to buy

RYTM - the stock has approached the lower boundary of the uptrend starting on 3/16/20. Support levels other than the trend line are:
- two VWAP lines: 1st from the minimum value (3/16/20) and 2nd from the IPO date.
- 200D EMA
- Support zone, which has already been repeatedly tested.
MACD indicator is in the negative zone and has crossed the signal line.

Presentations at the Annual Meeting and Expo of the Endocrine Society (ENDO 2021) on March 20-23 might be a potential driver in the near term.

The average target for the stock is $46.25, the current price is 26.09. Upside 77%.

According to Form 8-K, the company has enough equity until the second half of 2023.

Nearest growth targets are $32.2, $36.2. Stop below $24.6.

This point of view is my personal view and is not invest recommendation.